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sequencing results showed
vaccine–derived poliovirus; the deci-
sion was made to launch an outbreak
response immunization for 175,000
children  <5 years of age living in
Loei, Khonkaen, and Nongbualampoo
provinces (visited by the patient from
March to August 2003). Two-round
campaigns were conducted in August
and September. The estimated vaccine
coverage was >95%. 
Considering the rate of 1% genom-
ic diversity per year and the immun-
odeficient status of the patient (2), he
should have harbored the vaccine
strain virus since he received the first
dose of routine oral polio vaccine
immunization at 2 months of age, and
the virus was replicated in his gut.
However, why the virus disappeared
in subsequent stool specimens is
unknown. Circulating vaccine–
derived poliovirus is unlikely in this
event, as we found no evidence of
recombination with other nonpolio
enterovirus, high oral polio vaccine
coverage in the community, and no
vaccine–derived poliovirus in other
children.
Although immunoglobulin levels
in this case were low but still
detectable, whether the patient’s ill-
ness was agammaglobulinemia or
hypogammaglobulinemia is uncer-
tain. The detected immunoglobulin
levels, as well as the antibody level to
poliovirus, may be due to intravenous
immunoglobulin (IVIG) the patient
received while hospitalized 4 months
before testing. Since August 2003, the
patient has been on IVIG replacement
therapy after prolonged and repeated
respiratory tract infections.
In retrospect, problems surrounded
this event. First, because of several
attempts to confirm the result, identi-
fication of strain differentiation was
delayed. Second, genetic sequencing
was delayed because of a communica-
tion gap associated with new bioter-
rorism regulations in the United States
during specimen transfer. Third,
knowledge of a possible immune defi-
ciency in the previously healthy child
was lacking, testing for the patient’s
immune status was delayed. 
Acknowledgment
We thank Siriraj Hospital, the
Centers for Disease Control and
Prevention, and Suchitra Nimmannitya.
Piyanit Tharmaphornpilas* 
for the Outbreak Response 
Team, Thailand1
*Ministry of Public Health, Nonthaburi,
Thailand
References 
1.  Division of General Communicable
Disease, Ministry of Public Health.
National documentation for certification of
poliomyelitis eradication, Thailand, 2003
[official document].
2. Khetsuriani N, Prevots DR, Quick L, Elder
ME, Pallansch M, Kew O, et al. Persistence
of vaccine–derived polioviruses among
immunodeficient persons with vaccine-
associated paralytic poliomyelitis. J Infect
Dis. 2003;188:1845–52.
Address for correspondence: Piyanit
Tharmaphornpilas, EPI manager, Department
of Disease Control, Ministry of Public Health,
Nonthaburi, 11000, Thailand; fax: 66-2-
5918425; email: piyanit@health.moph.go.th
Toscana Virus and
Acute Meningitis,
France 
To the Editor: Sandfly fever
Naples virus, Sandfly fever Sicilian
virus, and Toscana virus (family
Bunyaviridae, genus Phlebovirus)
have been recognized as etiologic
agents of human illnesses in European
countries bordering the Mediterra-
nean Sea. These viruses are responsi-
ble for rapidly resolving diseases with
nonspecific symptoms such as fever
and myalgia. However, infection with
Toscana virus may involve the central
nervous system; severity may range
from aseptic meningitis to menin-
goencephalitis (1). In most cases, ill-
nesses caused by Toscana virus
mimics a flulike syndrome with fever,
photophobia, headache, red eyes, and
stiff neck. Recently, 2 cases of
Toscana virus meningoencephalitis in
patients with unusual symptoms and
life-threatening complications were
described in Italy (2). However,
sequelae have never been reported.
Toscana virus infection is now epi-
demic in Italy and Spain (1,3).
Furthermore, sporadic cases have
been reported in travelers returning
from Italy, Spain, Greece, Portugal,
and the South of France (4–6). The
epidemiology of Toscana virus in
France is still unknown. Although
infections with this virus have been
diagnosed by serologic tests in French
patients and in tourists residing in
southeastern France, this pathogen
has reportedly never been isolated in
France (7,8). Here we describe the
clinical and biologic features of
autochthonous meningitis due to
Toscana virus.
On July 9, 2004, a 57-year-old
woman who had never left the south-
eastern coast of France reported
malaise and vomiting. On hospital
admission, her body temperature was
38.5°C, and clinical examination
showed photophobia and stiff neck.
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Skin and abdomen were normal.
Cardiopulmonary and neurologic
functions were also normal. Analysis
of hematologic and biochemical
blood tests revealed mild hyper-
glycemia (6.88 mmol/L) and elevated
γ-glutamyltransferase (104 IU/L) and
C-reactive protein levels (57 mg/L).
Cerebrospinal fluid (CSF) analysis
showed 3,500 leukocytes/µL (70%
lymphocytes, 30% neutrophils), and
glucose and protein levels of 2.5
mmol/Land 2.749 mg/L, respectively.
Blood and CSF cultures were bacteri-
ologically sterile. Polymerase chain
reaction (PCR) assays of CSF for her-
pes simplex virus were also negative.
The patient received intravenous
amoxicillin and acyclovir for 3 days.
The patient recovered after 6 days
without sequelae. 
Serum and CSF samples collected
during the acute phase were tested for
immunoglobulin (Ig)M and IgG anti-
bodies to a battery of arboviruses.
These samples contained no antibod-
ies (optical density [OD] ratio <1.5) to
flaviviruses, dengue virus, West Nile
virus, and tickborne encephalitis,
Tahyna virus, or Sandfly fever
Sicilian virus (Table). However, the
IgM OD ratios (>2.5) obtained against
Toscana virus antigen were high. A
second serum sample tested 1 month
later showed seroconversion to
Toscana virus with OD ratios >3 for
both IgM and IgG (Table).
Virus isolation was attempted by
incubation of peripheral blood
mononuclear cells and CSF collected
on the day of onset with C6/36 (Aedes
albopictus) and Vero (E6 clone)
monolayers. Toscana virus was found
only on Vero cells by indirect
immunofluorescence by using mouse
hyperimmune ascitic fluid against
Toscana virus. In contrast, no fluores-
cence was found by using mouse
hyperimmune ascitic fluids against
Rift Valley fever and Sandfly fever
Sicilian virus. 
S segment of Toscana virus
genome was partly amplified from
culture supernatants by reverse-tran-
scription PCR and sequenced (9).
Nucleotide and peptide sequences
obtained (GenBank accession no.
AY766034) displayed 87% and 100%
identity, respectively, with Toscana
virus sequences available on
GenBank database, thus confirming
the infection by Toscana virus. 
Toscana virus, transmitted to
humans by Phlebotomus vectors, has
been recognized as a major cause of
aseptic meningitis in Italy and Spain.
P. perniciosus, proven to be a vector of
Toscana virus (10), is abundant along
the French Mediterranean coast. The
isolation of an autochthonous Toscana
virus strain shows that the conditions
of an efficient transmission cycle were
combined in southern France. Until
now, human infection by Toscana virus
was fortuitously detected by serologic
means, suggesting that subclinical
infection may also occur (8). Thus,
Toscana virus infection in France like-
ly has been underestimated. Moreover,
meningitis caused by Toscana virus
has been underestimated and other dis-
eases caused by Toscana virus may
have also been underestimated. The
requirement for virus growth in cell
culture delays a diagnosis based on
viral isolation, which is limited by the
transitory presence of the virus in
blood or CSF. As reported here,
Toscana virus infection was only con-
firmed after the patient relapsed.
Considering that signs and symptoms
of Toscana virus meningitis are not
pathognomic, this case highlights the
need for rapid and specific diagnostic
tools, such as PCR assays, to identify
infections caused by Toscana virus and
other neurotropic viral agents.
Moreover, a systematic serologic study
of recovered meningitis patients may
help to better characterize viral menin-
gitis of unknown etiology.
Finally, this work suggests that, in
addition to West Nile virus, Toscana
virus should now be considered as a
potential etiologic agent of acute
meningitis in the southeastern part of
France. Entomologic and epidemio-
logic surveys, however, will have to
be conducted in the near future to
determine the risk for the people liv-
ing in that area.
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Helicobacter pylori,
Republic of
Georgia 
To the Editor: Helicobacter pylori
infection is a principal cause of chron-
ic active gastritis and peptic ulcer dis-
ease as well as gastric adenocarcino-
ma and mucosa-associated lymphoid
tissue lymphoma (1). Poverty and
crowding have been associated with
infection epidemiologically (2,3). The
Republic of Georgia has a per capita
annual income of US $591, making it
one of the poorest countries in the
world (4,5). Georgia also reports a
high annual incidence of gastric can-
cer, 17/100,000 population in 2002
(National Center for Disease Control,
Tbilisi, unpub. data), which suggests
an elevated prevalence of H. pylori
infection. Testing and treatment for H.
pylori are not practiced in this coun-
try, and diagnostic capacity for H.
pylori is nonexistent. In October
2003, we conducted an exploratory
pilot study of H. pylori infection to
begin characterizing prevalence and
risk factors for infection. 
We studied a convenience sample
of adults residing in or near the capi-
tal city of Tbilisi. Urban participants
were recruited in 11 of Tbilisi’s 12
residential districts and in 1 district of
Rustavi, a city 20 miles south of
Tbilisi. Rural participants were
recruited from 3 villages within 10
miles of Tbilisi. In each district or vil-
lage, we nonsystematically selected
10 households and recruited 1 adult
per household. Exclusion criteria
included age <18 years; reported
allergy to omeprazole, clar-
ithromycin, or amoxicillin; or treat-
ment with any antimicrobial agent
within the preceding 2 weeks. This
protocol was reviewed and approved
by the Human Subjects Review Board
at the National Center for Disease
Control, Tbilisi. Active infection with
H. pylori was measured by a validat-
ed, point-of-care 13C-urea breath test
(Meretek Corporation, Lafayette, CO,
USA) (6). Participants responded to a
questionnaire that requested informa-
tion about gastrointestinal symptoms
during the preceding 12 months; diag-
nosis of gastritis, peptic ulcer disease,
and gastric cancer made by a physi-
cian; family history of peptic ulcer
disease or gastric cancer; and knowl-
edge about H. pylori. Low, medium,
or high socioeconomic status cate-
gories were designated on an ecologic
basis, according to average real estate
prices and common perception of the
living standard of the participant’s
district or village of residence.
Analyses were conducted with SAS
(SAS Institute, Cary, NC, USA) ver-
sion 9.0. Measures of inference are
not reported because participants did
not constitute a rigorously selected
population sample.
Of 136 persons eligible to partici-
pate in the study, 135 (99%) consent-
ed to take part. Median age was 39
(range 19 – 79); 82 participants (61%)
were women. Twenty-seven (20%)
reported having some knowledge of
H. pylori, but none had been tested or
treated for the infection. Ninety-seven
(72%) participants had active H.
pylori infection: 58 (71%) of 82
women and 39 (74%) of 53 men.
Thirty (77%) of 39 participants >50
years of age tested positive for H.
pylori compared to 67 (70%) of 96
participants <50 years of age.
Seventy-one (84%) of 85 partici-
pants residing in neighborhoods of
low-socioeconomic status were
infected versus 26 (52%) of 50 partic-
ipants residing in neighborhoods of
medium- or high-socioeconomic sta-
tus (crude prevalence odds ratio 4.68).
Twenty-three (85%) rural participants
were infected compared to 74 (69%)
of 108 urban participants (crude
prevalence odds ratio 2.64).
Gastrointestinal symptoms were
common, but did not correlate with
active infection. One hundred five
participants (78%) reported recurrent
epigastric pain within the past year;
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